Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a study titled A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression. The study aims to evaluate the safety and efficacy of Mirvetuximab Soravtansine, an investigational antibody drug conjugate, in targeting cancer cells with high folate receptor alpha expression.
The treatment involves administering Mirvetuximab Soravtansine intravenously. It is designed to deliver a cell-killing drug specifically to cancer cells. The study includes two cohorts: a Randomized Phase 2 Cohort with two treatment arms receiving different dosing schedules, and a Hepatic Impairment Cohort to determine the starting dose for patients with moderate liver impairment.
This interventional study follows a randomized, parallel assignment model without masking, primarily for treatment purposes. Participants are allocated into different groups to receive the drug on varied schedules to optimize dosing.
The study began on May 28, 2025, with an estimated total duration of 24 months. The last update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and ensuring timely completion.
The study’s outcome could significantly impact AbbVie’s stock performance, as positive results may enhance investor confidence and market position. With the competitive landscape in cancer treatment, successful trials could position AbbVie favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.